CHA
ALXN

Carmichael Hill & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Carmichael Hill & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11
Closed -$2K – 829
2021
Q2 		$2K Sell
11
-4
-27% -$687 ﹤0.01% 747
2021
Q1 		$2K Hold
15
– – ﹤0.01% 728
2020
Q4 		$2K Hold
15
– – ﹤0.01% 699
2020
Q3 		$2K Hold
15
– – ﹤0.01% 673
2020
Q2 		$2K Hold
15
– – ﹤0.01% 644
2020
Q1 		$1K Hold
15
– – ﹤0.01% 679
2019
Q4 		$2K Buy
+15
New +$1.6K ﹤0.01% 655

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Carmichael Hill & Associates's ALXN Position: Q3 2021 in Review

Carmichael Hill & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11 shares — an estimated $2K sold.

Carmichael Hill & Associates first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $2K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Carmichael Hill & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 11 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2K.
  • Carmichael Hill & Associates first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Carmichael Hill & Associates's Alexion Pharmaceuticals position peaked at $2K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Carmichael Hill & Associates's 13F filing for Q3 2021, filed 12 Nov 2021.